Gilead Sciences buys Interius Bio for $350M

Gilead Sciences, whose Kite subsidiary was one of the pioneers of ex vivo cancer cell therapy, is joining the pursuit of in vivo therapies with the acquisition of startup Interius BioTherapeutics. The deal follows AstraZeneca and AbbVie acquisitions this year for in vivo cell therapy developers.

Editor's Pick

Top Story Gilead Sciences Gains In Vivo Cell Therapy Capability With $350M Interius Bio Acquisition Gilead Sciences, whose Kite subsidiary was one of the pioneers of ex vivo cancer cell therapy, is joining the pursuit of in vivo therapies with the acquisition of startup Interius BioTherapeutics. The deal follows AstraZeneca and AbbVie acquisitions this year for in vivo cell therapy developers. Sponsored 6 Aesthetic Certification Programs That Include Both Theory and Practical Training Presented by American Association of Aesthetic Medicine and Surgery Explore top-tier aesthetic certification programs that blend theory with hands-on training — perfect for health care pros ready to elevate their practice. Learn more! We Want Your Feedback Your voice helps shape the stories, insights, and events we deliver. Take just a few minutes to complete our short, anonymous audience survey and let us know what you enjoy and what you'd like to see more of. As a thank you, you'll be entered for a chance to win a $250 Amazon gift card. Take Survey Now

Featured News

MedCity Pivot Podcast: Clinical Documentation Improvement With Smarter Technologies [Sponsored] Smarter Technologies CEO Jeremy Delinsky explains how the company's AI infrastructure can help support health system's clinical documentation improvement efforts, ultimately strengthening RCM. Array Behavioral Care Introduces Model for Standardizing Mental Health Treatment Array Behavioral Care introduced a new model called Care Pathways, which aims to make mental health treatment more consistent and personalized while also improving patient outcomes. Could Small Cash Prizes Motivate People to Be Healthier? Investors Say Yes Digital health engagement app Wellth raised $36 million in Series C funding to expand its "daily care motivation platform," which uses small financial incentives and dopamine-driven nudges to keep patients engaged in healthy behaviors. Protecting Your Biotech: Understanding the Risks of Compounded GLP-1s With the global market for anti-obesity drugs projected to hit $95 billion by 2030, it's no surprise that compounded semaglutide is gaining traction as a cheaper, more accessible option. But for all its appeal, this route comes with real risks: regulatory uncertainty, legal exposure, and major insurance hurdles. Connecting Siloed Data Facilitates Interoperability and Helps Maintain Care Continuity Across the Behavioral Health Patient Journey A combined bottom-up facility-level approach to integrated data and a top-down national-level effort for connected networks is needed to eliminate data silos and deliver frictionless care.

Video   Should For-Profit Companies Be Administering Medicare Advantage Plans? The House Ways and Means Committee's joint oversight and health subcommittee hearing on Medicare Advantage focused on fraud, waste and abuse.  The hearing had seven witnesses, and two of them were the CEOs of Medicare Advantage plans Alignment Health and Scan Health. Notably absent were several large payers, like UnitedHealthcare and Humana, despite past investigations and fines.  This begs the question: should for-profit health plans even be in the business of selling Medicaid Advantage plans?

Sponsored The Definitive Guide to Medical Billing Outsourcing: 5 Top Companies Presented by Global Healthcare Resource In today's healthcare landscape, your choice of medical billing partner directly impacts your bottom line. What are the best medical billing outsourcing companies, and which one is right for you? Learn More.

Resources

MedCity FemFwd: Advancing Value-Based Care in Women's Health In this episode, we're joined by Dr. Keith Berkle, chair of the Privia Medical Group — Mid-Atlantic Board of Governors and president of Virginia Women's Center, who discusses the challenges OBGYNs face in transitioning to value-based care. View Now

MedCity News • PO Box 901 • New York, NY unsubscribe